X4 Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held by X4 Pharmaceuticals, Inc. on June 6, 2022. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Boston, Massachusetts. Its common stock trades on The Nasdaq Stock Market LLC under the symbol "XFOR".
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected William E. Aliski, M.P.A. and Alison Lawton to the Board of Directors. Both nominees will serve until the 2025 Annual Meeting.
- William E. Aliski, M.P.A.: 10,728,960 votes For; 3,519,016 votes Withheld; 7,760,776 Broker Non-Votes.
- Alison Lawton: 10,727,988 votes For; 3,519,988 votes Withheld; 7,760,776 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders approved the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes: 21,893,224 For; 68,938 Against; 46,590 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the new Board composition with William E. Aliski and Alison Lawton serving until 2025.
- Verification that PricewaterhouseCoopers LLP is the appointed auditor for the 2022 fiscal year.
- Review of the significant number of Broker Non-Votes (7,760,776) recorded for the director elections.